An agency that runs two separate programs. Clinician advocates and patient advocates reach different audiences under different rules, and a single program aimed at both will breach something in one direction while underperforming in the other.
Table of Contents
- Two audiences, two programs
- The off-label problem is the shared risk
- Depiction of use is instruction
- Adverse event obligations are continuous
- Patient advocates need particular care
- What to ask an agency
- The consumer-facing device exception
- Where the strongest content sits
- Sales representative content
- Program Delivery Across Regulated and Technical Categories
- The HireInfluence Model for Health Technology Categories
Medical devices sit between pharmaceutical and consumer health and are frequently treated as either. Medical device influencer marketing has to handle content showing a device in clinical use, patient advocates describing outcomes, and a professional audience that will identify an incorrect depiction immediately. The regulatory position differs from pharmaceutical and it is not lighter, only different. This article covers the operating requirements. It is not regulatory advice and device brands should work with regulatory counsel throughout.
Two audiences, two programs
Clinician-facing content reaches specifiers and users. The credibility comes from the person’s practice, the content is technical, and the format is long. This behaves like a practitioner advocacy program with heavy regulatory overlay.
Patient-facing content reaches people living with a condition or considering a procedure. The credibility comes from lived experience, the content is personal, and the risk is that a personal outcome reads as a general claim.
They should not share a roster, a brief, or a review path, and a proposal that merges them has misread the category.
The off-label problem is the shared risk
The single constraint that governs both programs.
Devices have cleared or approved indications, and content depicting use outside them is a problem regardless of who created it.
Clinicians discuss real practice, which legitimately includes uses beyond the labeled indication, and a clinician advocate describing their own approach may describe exactly that.
Patients describe their own experience, which may involve a use the label does not cover.
Comments are where it surfaces. A clinician answering a colleague’s question, or a patient answering another patient’s, produces off-label discussion in a space nobody is reviewing.
The controls: an explicit indication statement supplied to every advocate, a prohibition on discussing uses beyond it, comment handling instructions with an escalation path, and post-publication monitoring rather than briefing alone.
Depiction of use is instruction
Content showing a device in use teaches use. For devices with technique-dependent outcomes or safety-critical handling, an incorrect depiction is a hazard.
Setting matters. Content filmed in a clinical environment captures other patients, staff, and equipment, and consent and privacy obligations apply to all of them.
Sterile field and infection control shown incorrectly is visible to every clinician watching and damages credibility with the audience the content was made for.
Review should include somebody with clinical or technical knowledge of the device, not a marketing reviewer alone.
Adverse event obligations are continuous
The operational point brands most often miss.
A comment describing a device malfunction, an injury, or an unexpected outcome may constitute a reportable event. That means somebody has to monitor comments across every live asset, with a defined escalation into the brand’s complaint handling and vigilance process, for as long as the content remains published.
This is a resourcing commitment rather than a campaign task, and it should be scoped and priced explicitly rather than assumed. An agency that has not raised it has not run a regulated health category.
Patient advocates need particular care
The condition is the reason they are compelling and it is also sensitive personal information they are choosing to make public. Consent should be informed, specific about uses including paid amplification, and revocable.
Outcome framing is the whole risk. What happened to one patient, with their clinical picture, is a story. The same content without that context is an efficacy claim.
Compensation creates a material connection requiring disclosure, and the emotional weight of patient content makes clear disclosure more important rather than less.
Long-term content ages. A patient whose outcome changes leaves content on the internet describing a result that is no longer their experience, and the agreement should address what happens then.
What to ask an agency
How are the clinician and patient programs separated?
Who monitors comments for adverse events, and what is the escalation path?
Who reviews depiction of use for technical correctness?
How is the indication statement supplied and enforced?
How are clinician employment and payment transparency obligations handled?
The consumer-facing device exception
A growing part of the category sells directly to consumers, and it is treated as ordinary consumer marketing more often than it should be.
Wearables, monitors, and at-home diagnostics may still be regulated devices with cleared indications, even where they are bought in a shop.
The claim boundary is where brands get caught. A device cleared to measure something is not cleared to diagnose, manage, or treat, and creator content describing what it helped them understand about their health drifts across that line naturally.
The audience assumes clinical authority that the clearance may not support.
Brands in this part of the category should apply the indication discipline described above rather than the consumer electronics playbook, because the product’s regulatory status does not change when the buyer does.
Where the strongest content sits
Device brands default to product demonstration and the better material is elsewhere.
Condition and procedure education reaches patients before they know a device exists, which is earlier in the decision than product content can reach.
Clinician technique and practice content serves the specifier audience and travels within professional communities.
Access and reimbursement content addresses the barrier that actually prevents adoption in many cases, and almost nobody produces it. A patient who wants a device and cannot establish whether it will be covered is a lost sale that no amount of product content recovers.
Living-with content from patients describes the ongoing reality rather than the outcome moment, which is what prospective patients are trying to understand.
All four carry lower claim exposure than product demonstration and reach the audience earlier.
Sales representative content
Device companies field large commercial teams who are already in operating rooms and clinics, and their content is both an opportunity and an exposure.
Representatives post about their work, frequently without any guidance, and content from a clinical setting raises every consent and confidentiality question this article has covered.
Their credibility with clinicians is real, which makes structured advocacy genuinely valuable.
Disclosure is unambiguous: an employee promoting their employer’s device has a material connection.
A written policy covering what representatives may photograph, post, and claim is the minimum, and a structured program turns an existing unmanaged behavior into a controlled asset. The policy also protects the representative, who is otherwise improvising against rules nobody explained to them.
Program Delivery Across Regulated and Technical Categories
The #CoatYourThroat program for Ricola produced a 13.17% engagement rate, and the campaign is documented in full in the Ricola case study.
The #SouthwestSaysAloha program for Southwest Airlines delivered 56M impressions and 3M engagements. For MTV, the #MyMTVStyle program returned 16.1M impressions and 216,600 engagements at $0.01 CPV and $1.50 CPM.
Additional campaign detail is published in the work portfolio.
The HireInfluence Model for Health Technology Categories
Founded in 2011, HireInfluence is a full-service influencer marketing agency built for enterprise brands, headquartered in Houston with offices in Austin, Los Angeles, and New York. The firm runs creator programs for brands including Adidas, Coca-Cola, Microsoft, Oreo, Target, and Warner Bros, covering strategy, talent sourcing, branded content production, paid amplification, and performance reporting. Creator selection runs through a manual vetting and validation process rather than database filtering alone, and campaigns are scoped to each client’s objectives rather than sold as fixed packages.
Device brands should read the influencer content approval process and the FTC influencer disclosure guidelines for enterprise brands. Neither is regulatory advice. Scoping conversations start through contact.
